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Abstract
Background: Fetal akinesia/hypokinesia, arthrogryposis and severe congenital myopathies are heterogeneous
conditions usually presenting before or at birth. Although numerous causative genes have been identified for each
of these disease groups, in many cases a specific genetic diagnosis remains elusive. Due to the emergence of next
generation sequencing, virtually the entire coding region of an individual’s DNA can now be analysed through
“whole” exome sequencing, enabling almost all known and novel disease genes to be investigated for disorders
such as these.
Methods: Genomic DNA samples from 45 patients with fetal akinesia/hypokinesia, arthrogryposis or severe
congenital myopathies from 38 unrelated families were subjected to next generation sequencing. Clinical features
and diagnoses for each patient were supplied by referring clinicians. Genomic DNA was used for either whole
exome sequencing or a custom-designed neuromuscular sub-exomic supercapture array containing 277 genes
responsible for various neuromuscular diseases. Candidate disease-causing variants were investigated and
confirmed using Sanger sequencing. Some of the cases within this cohort study have been published previously as
separate studies.
Results: A conclusive genetic diagnosis was achieved for 18 of the 38 families. Within this cohort, mutations were
found in eight previously known neuromuscular disease genes (CHRND, CHNRG, ECEL1, GBE1, MTM1, MYH3, NEB and
RYR1) and four novel neuromuscular disease genes were identified and have been published as separate reports
(GPR126, KLHL40, KLHL41 and SPEG). In addition, novel mutations were identified in CHRND, KLHL40, NEB and RYR1.
Autosomal dominant, autosomal recessive, X-linked, and de novo modes of inheritance were observed.
Conclusions: By using next generation sequencing on a cohort of 38 unrelated families with fetal akinesia/
hypokinesia, arthrogryposis, or severe congenital myopathy we therefore obtained a genetic diagnosis for 47 % of
families. This study highlights the power and capacity of next generation sequencing (i) to determine the aetiology
of genetically heterogeneous neuromuscular diseases, (ii) to identify novel disease genes in small pedigrees or
isolated cases and (iii) to refine the interplay between genetic diagnosis and clinical evaluation and management.
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Fetal akinesia deformation sequence (FADS) or Pena
Shokeir syndrome, characterized by intrauterine growth
retardation, contractures, craniofacial anomalies, limb
anomalies, pulmonary hypoplasia and polyhydramnios,
results from reduced movement in utero [1, 2]. A num-
ber of other fetal akinesia syndromes overlap phenotyp-
ically with FADS. These include the lethal congenital
contracture syndromes, multiple pterygium syndromes,
and arthrogryposis multiplex congenita [3], in which the
clinical findings are dependent upon the time of onset of
the dyskinesia, earlier onset being associated with a
more severe phenotype [2]. It’s thought that more than
50 % of all causes of fetal akinesia are of neuromuscular
origin [4]; at least 30 causative genes have been identi-
fied, involving all points along the neuromuscular axis
(motor neurons, peripheral nerves, neuromuscular junc-
tion and the skeletal muscle regulatory and contractile
apparatus) [5–7].
Arthrogryposis
Arthrogryposis refers to non-progressive congenital joint
contractures in >1 area of the body, and has been de-
scribed in more than 300 specific disorders [6, 8].
Arthrogryposis is thought to result from reduced fetal
movement, and affects approximately 1 in 3,000 live
births [8, 9]. There is a range of disease severity: severe
cases present with arthrogryposis multiplex congenita,
which is lethal prior to or at birth, while milder cases
with a longer life expectancy may have predominantly
distal involvement [8, 9]. The distal arthrogryposes are a
group of disorders with contractures primarily involving
the extremities of the body, often associated with camp-
todactyly, hypoplastic or absent flexion creases, and tali-
pes equinovarus [10, 11]. There are ten distinct subtypes
of distal arthrogryposis, for which seven causative genes
have been identified: ECEL1 (OMIM 605896), MYH3
(OMIM 160720), MYH8 (OMIM 160741), PIEZO2
(OMIM 613692), TNNI2 (OMIM 191043), TNNT3
(OMIM 600692) and TPM2 (OMIM 190990) [11–13].
Congenital myopathies
The congenital myopathies are a diverse group of disor-
ders, characterised by skeletal muscle dysfunction (most
often weakness and hypotonia), with specific morpho-
logical features on skeletal muscle biopsies [14, 15].
Three distinct major groups are recognized based upon
the presence of one or more major histopathological fea-
tures: centronuclear myopathy, core myopathy and
nemaline myopathy (NEM), although there is extensive
overlap in both genotype and phenotype within and be-
tween these groups [16, 17]. While muscle biopsy re-
mains critical for diagnosis, there can be overlap in the
morphological abnormalities seen in these conditions,
and marked variability in their clinical progression and
severity [14, 15]. The clinical spectrum of the congenital
myopathies ranges from severe fetal akinesia to adult-
onset progressive weakness. Typical features of these
conditions include proximal weakness, respiratory insuf-
ficiency, facial weakness, skeletal deformities such as hip
dislocation and deformities of the feet, feeding difficul-
ties, hypotonia and delayed motor milestones [17], how-
ever hypertonic cases are also encountered [15, 18].
More than 15 disease genes are known to cause
congenital myopathies. However, many cases remain
genetically unresolved, suggesting further heterogen-
eity [5, 7, 12, 19–21]. This study aimed to assess the
potential of next generation sequencing technologies
to identify causative genes in small families or iso-
lated probands presenting with fetal hypokinesia,
arthrogryposis or a severe congenital myopathy.
Methods
Subject information and study ethics approval
Informed consent was given for participation in this
study, which was approved by the Human Research
Ethics Committee of the University of Western
Australia, Perth, Western Australia, Australia.
Exome sequencing
Exome sequencing for this study was performed at the
Lotterywest State Biomedical Facility Genomics Node
(LSBFG) in Perth, Australia. Exome sequencing was
performed on the 5500XL SOLiD™ system (Applied
Biosystems), as described elsewhere [20, 22–24], and the
Ion Proton™ (Ampliseq chemistry, Life Technologies)
(Family 16 and 38). For AmpliSeq exome sequencing,
100 ng of DNA from the probands was amplified in 12
PCR pools and sequencing adaptors ligated. The library
was then purified using AMPure beads (Beckman
Coulter), and amplified using Platinum® High-Fidelity
Taq Polymerase. The amplified library was again purified
with AMPure beads and analysed on a 2100 Bioanalyser
(Agilent Technologies Genomics). Libraries were diluted
to 18-26pM and attached to Ion Sphere™ Particles using
an Ion Proton™ Template 200 v3 kit and sequenced on a
P1 sequencing chip on an Ion Proton sequencer™ (Ion
Sequencing 200 kit v3) in pools of two.
Targeted capture and sequencing of neuromuscular
disease genes by next generation sequencing
Neuromuscular sub-exomic sequencing (NSES) was also
performed at the LSBFG. The NSES panel comprised
those genes listed within the December 2012 freeze of
Neuromuscular Disorders gene table [25] in which the
disease-causing mutations could be identified by next
generation sequencing, some unpublished candidate
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disease genes identified by our group and others and 59
cardiomyopathy genes. NSES analysis was performed on
DNA from the probands using the Ion Proton™ sequen-
cer (Life Technologies), as previously described [26]. For
NSES, 2 μg of DNA was captured in pools of 16 DNA
samples using a custom TargetSeq™ (Life Technologies)
capture system, enriching for the 336 known and candi-
date neuromuscular and cardiomyopathy disease genes.
These captured pools were then sequenced in batches of
16 using an Ion P1 200 V2 sequencing kit (Life
Technologies) for 520 flows.
Bioinformatics
Variant calling was performed against the GRCh37 hu-
man reference genome, using LifeScope™ 2.5 (exome se-
quencing) and Torrent Suite V 3.6.2 (NSES) (Life
Technologies). Data was filtered using an ANNOVAR
annotation software suite. Variants were annotated using
the EncodeGencode gene annotation set. Variants were
filtered against the 1000 Genomes database (2012 re-
lease, [27]) and the dbSNP137 common database, and
variants with a frequency of >0.5 % were excluded. Vari-
ants were then filtered against an in-house common
variant list and were checked against the HGMD profes-
sional database to identify any known disease-causing
mutations. The frequencies of candidate disease variants
in the 1000 Genomes Project, Exome Variant Server
(http://evs.gs.washington.edu/EVS/) and ExAC Browser
(http://exac.broadinstitute.org) were also determined.
Pathogenicity predictions were made using online pre-
diction software programs: SIFT, PolyPhen [28], and
MutationTaster [29].
The LSBFG has a cut-off of 90 % of on-target regions
covered to 20-fold or greater for the neuromuscular
panel (NSES) and 80 % covered to 20-fold or greater for
exome sequencing, however some samples, especially
early samples, did not achieve these cut-offs (Additional
file 1: Table S1). There was no significant difference in
the average coverage (mean ± SEM) of exome sequen-
cing data for genetically resolved (80 ± 14-fold; n = 15)
versus unresolved cases (70 ± 8-fold; n = 23). For the
NSES panel, average coverages were 220 ± 23-fold (n = 6)
for resolved cases versus unresolved cases (195 ± 13-fold,
n = 9). Thus coverage is unlikely to contribute to the lack
of a genetic diagnosis in most cases.
Sanger confirmation and co-segregation studies
PCR amplification and Sanger sequencing was per-
formed to verify potential mutations identified by next
generation sequencing. Co-segregation was also verified
for all existing family members where available. Primers
were based on genomic and cDNA sequences obtained
from the UCSC Human Genome Browser (http://geno-
me.ucsc.edu/) and Ensembl (http://www.ensembl.org/).
Primer sequences and conditions are available upon re-
quest. Sanger sequencing data was processed by LSBFG
and results viewed using CodonCode Aligner software.
Functional studies of the CHRND missense substitution
The mutation CHRND p.Cys257Arg was directly intro-
duced into the wild-type human delta subunit cDNA in
the vector pcDNA3.1/hygro (−) by site-directed muta-
genesis (QuikChange® Site-Directed Mutagenesis Kit,
Stratagene, Amsterdam, The Netherlands). Primer se-
quences can be obtained on request. To confirm the
presence of the introduced mutation, and to rule out
any errors, the construct was subjected to Sanger
sequencing.
Wild-type and mutant human AChR δ-subunits
cDNAs in the vector pcDNA3.1/hygro (−) (Life
Technologies, V875–20) were used for transfection
studies.
Wild-type and mutant AChR δ-subunit cDNAs, in
combination with wild-type α-, β-and ɛ-subunit cDNAs,
were transfected into HEK 293 cells grown on six-well
tissue culture plates using polyethyleneimine. Surface
AChR expression was determined 2 days post-
transfection by incubating cells in 10 nM 125I-α-bun-
garotoxin (125I-α-BuTx) with 1 mg/ml BSA for 30
minutes. Cells were washed three times with PBS and
extracted in 1 % Triton X-100, in 10 mM Tris–HCl
(pH 7.4), 100 mM NaCl, 1 mM EDTA and 125I-α-BuTx
binding determined using a gamma counter.
Results and discussion
A total of 45 subjects from 38 families (including ten
consanguineous pedigrees) diagnosed with FADS,
arthrogryposis, or a severe congenital myopathy were in-
cluded in this study. Of these seven probands were sub-
mitted for NSES only, eight families had probands
sequenced using both NSES and exome sequencing,
and 23 families underwent only exome sequencing
(Additional file 1: Table S1). Families were grouped
into three disease entities: FADS (n = 9), arthrogrypo-
sis (n = 13), and severe congenital myopathies (n = 16).
Clinical details for the genetically resolved families
are summarized in Table 1.
A conclusive genetic diagnosis was achieved for 18/38
families (47 %, Table 2). This included two kindreds with
FADS, six with arthrogryposis and 10 presenting with a
congenital myopathy. From these results, autosomal
dominant (n = 1), autosomal recessive (n = 15), de novo
(n = 1) and X-linked (n = 1) modes of inheritance were
identified. Mutations were identified in eight previously
known neuromuscular disease genes. As part of this co-
hort study, four then novel disease genes were initially
identified from five families (Families 3, 4, 5, 12 and 38)
in the cohort and these families have been previously
Todd et al. Orphanet Journal of Rare Diseases  (2015) 10:148 Page 3 of 14
Table 1 Summary of the clinical features of the affected individuals within each family, not described previously





















16 yes II:1 birth C/S
(35wg)
7w 1,660 yes AMC yes no yes absent no yes none yes
20 yes II:VI birth C/S
(37wg)
(<1w) NI NI NI NI NI NI NI NI NI n/r NI
14 no II:2 birth C/S 5 m 3,196 yes no no no no hypotonic yes yes delayed yes
6 yes II:1 birth C/S
(30wg)
(3w) 1,345 NI AMC no NI NI absent yes no n/r yes
II:3 32wg C/S
(36wg)
(4w) 2,345 yes AMC no yes yes absent yes no n/r yes
8 no II:1 25wg in utero
demise
(26wg) NI yes AMC no yes NI n/r yes n/r n/r n/r
II:3 29wg in utero
demise
(29wg) 970 yes AMC no no yes n/r no n/r n/r n/r
13 no II:2 birth C/S
(38wg)
59/12y 3, 200 yes no yes no no hypotonic yes no delayed no
9 yes II:1 19 wg TOP
(19wg)
n/r NI NI AMC no yes NI n/r NI n/r n/r n/r
II:2 16wg TOP
(16wg)
n/r 98 yes AMC no yes yes n/r yes n/r n/r n/r
II:3 16wg TOP
(16wg)
n/r 95 yes AMC no yes yes n/r yes n/r n/r n/r
10 no II:1 20 wg C/S
(37wg)
(4w) 2,820 yes AMC no no yes hypotonic yes yes n/a yes
II:2 16wga TOP
(17wg)
n/r n/r no AMC no no NI n/r NI n/r n/r n/r
15 no II:2 NI NI 8y NI NI DA no NI NI normal no no normal no
1 no II:2 birth C/S 4y 3504 yes DA2A no no no normal yes yes delayed no
11 no I:2 birth C/S NI NI no DA2B no no no yes no no NI no
II:1 antenatal C/S NI 3,410 no DA2B no no no yes no no normal no














published: GPR126 (Family 3) [30], KLHL40 (Family 10
and 17; OMIM 615340) [24], KLHL41 (Patient ID: D12-
203; OMIM 607701) [22] and SPEG (Patient ID: P3;
OMIM 615950) [20].
Mutations in fetal hypokinesia and congenital myopathy
genes
KLHL40
Since our initial publication of KLHL40 as a novel NEM
gene, two further families within our cohort were shown
to have mutations in KLHL40 (Families 16 and 20). A
previously-unpublished homozygous nonsense mutation
in KLHL40 (exon 1, c.46C>T, p.Gln16*) was identified in
a proband from consanguineous parents (Family 16,
Fig. 1a). This proband was born by emergency Caesarean
section at 35/40 weeks gestation and presented with se-
vere arthrogryposis, congenital fractures, respiratory in-
sufficiency and complete akinesia. An initial clinical
diagnosis of spinal muscular atrophy type 0 was made,
but both light and electron microscopy of the child’s
muscle biopsy demonstrated miliary nemaline bodies
(Fig. 2), adding to the body of evidence suggesting that
Table 2 Mutations identified via next generation sequencing
Family Chr Position Gene Exon/(Intron) Transcript c. DNA change Amino acid change Alleles in ExAC
3a,WES 3:42728042 KLHL40 1 NM_152393 c.932G>T p.Arg311Leu Not found
3:42730455 4 c.1516A>C p.Thr506Pro A:7/C:121308
4a,WES 3:42730521 KLHL40 4 c.1582G>A p.Glu528Lys G:8/A:120018
3:42730521 4 c.1582G>A p.Glu528Lys G:8/A:120018
16WES 3:42727156 KLHL40 1 c.46C>T p.Gln16* Not found
3:42727156 1 c.46C>T p.Gln16* Not found
20NSES 3:42728041 KLHL40 1 c.931C>A p.Arg311Ser C:6/A:121368
3:42728041 1 c.931C>A p.Arg311Ser C:6/A:121368
5a,WES 2:170382132_9 KLHL41 6 NM_006063 c.1748_1755del8 p.Lys583Thrfs*7 Not found
2:170382132_9 6 c.1748_1755del8 p.Lys583Thrfs*7 Not found
12a,WES 2:220331929_30 SPEG 12 NM_005876 c.2915_2916del2insA p.Ala972Aspfs*79 Not found
2:220331929_30 37 c.8270G>T p.Gly2757Val Not found
38a,WES, NSES 6:142729324 GPR126 16 NM_198569 c.2306T>A p.Val769Glu Not found
6:142729324 16 c.2306T>A p.Val769Glu Not found
14NSES 23:149809808 MTM1 8 NM_000252 c.595C>T p.Pro199Ser Not found
6WES 19:38951109 RYR1 20 NM_000540 c.2455C>T p.Arg819* C:1/T:121396
19:38980890 36 c.5989G>A p.Glu1997Lys Not found
8WES 19:38987106 RYR1 41 c.6721C>T p. Arg2241* C:20/T:120468
19:39071143 101 c.14645C>T p.Thr4882Met C:2/T:121280
13NSES 19:38946103 RYR1 15 c.1589G>A p.Arg530His G:8/A:121410
19:39071143 101 c.14645C>T p.Thr4882Met C:2/T:121280
9WES 2:152539199 NEB 29 NM_001164508 c.2920C>T p.Arg974* Not found
2:152539199 29 c.2920C>T p.Arg974* Not found
2a,WES 3:81698005 GBE1 (5) NM_000158 c.691+2T>C ? T:113/C:98680
3:81691968 7 c.956A>G p.His319Arg Not found
10WES 2:233394798 CHRND 7 NM_000751 c.769T>C p.Cys257Arg Not found
2:233398996 11 c.1315delG p.Val439Trpfs*11 Not found
15NSES 2:233406191_2 CHRNG 5 NM_005199 c.459dupA p.Val154Serfs*24 CA:32/C:121406
2:233406191_2 5 c.459dupA p.Val154Serfs*24 CA:32/C:121406
1WES 17:10544634 MYH3 18 NM_002470 c.2015G>A p.Arg672His Not found
11NSES 17:10549042 MYH3 12 c.1123G>A p.Glu375Lys Not found
7a,WES 2:233347865 ECEL1 9 NM_004826 c.1531G>A p.Gly511Ser Not found
2:233346560 (12) c.1797-1G>A ? Not found
aDenotes families published previously. Type of next-generation sequencing performed for each family is also noted in this table
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Fig. 1 Pedigrees for families in which mutations were identified from next generation sequencing of a proband. Pedigrees and segregation of
the mutation/s identified within each family is shown for pedigrees not previously described elsewhere. Probands denoted by arrowheads. (a)
Family 16 and (b) Family 20 with homozygous KLHL40 mutations; (c) Family 14: X-linked MTM1 mutation; (d) Family 6, (e) Family 8 and (f) Family
13 with compound heterozygous mutations of RYR1; (g) Family 9: homozygous NEB mutation; (h) Family 10: compound heterozygous mutation
of CHRND; i Family 15: homozygous mutation of CHRNG; (j) Family 1: de novo mutation of MYH3; (k) Family 11: dominantly-inherited mutation of
MYH3. Pedigrees for Family 223, 3-424, 522, 757, 1220 and 3830 are published previously
Fig. 2 Evolutionary conservations of substituted residues in three families harbouring novel missense substitutions. Evolutionary conservation of
the substituted amino acid in KLHL40 in Family 20 (a), RYR1 in Family 6 (b) and CHRND in Family 10 (c)
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miliary nemaline bodies are a good indicator suggesting
KLHL40 as the causative gene.
The proband in Family 20 was born to consanguineous
parents (Fig. 1b) by Caesarean section at 37 weeks gesta-
tion. He had profound hypotonia, an absent gag reflex,
myopathic facies, and was ventilated from birth, but sur-
vived only a few days. His muscle biopsy showed numer-
ous nemaline bodies. The family history included two
previous miscarriages, two neonatal deaths and a sibling
who died at seven months of age with suspected NEM
(light microscopy indicated rods, but electron micros-
copy was not performed). No mutations were found on
Sanger sequencing of ACTA1, but NSES showed a novel
homozygous missense mutation in KLHL40 (exon 1,
c.931C>A, p.Arg311Ser) affecting the same highly con-
served amino acid residue as that in Family 3 (Fig. 3a).
MTM1
The second male child of a non-consanguineous family
(Family 14, Fig. 1c) was born after an uncomplicated
pregnancy, by emergency Caesarean section for failure
to progress. The baby was weak and hypotonic at birth,
was very long (reported >90th percentile for length with
weight 10-25th percentile), had advanced bone age, and
initially required intubation. By age 5 months the infant’s
strength and spontaneous movement improved mark-
edly, but he had significant residual weakness and bulbar
dysfunction. NSES identified a known missense muta-
tion (exon 8, c.595C>T, p.Pro199Ser) in the myotubu-
larin gene (MTM1; OMIM 300415) [31] associated with
myotubular myopathy. A muscle biopsy taken at
10 weeks of age revealed hypoplastic myofibres, some
with internal nuclei, typical features of myotubular my-
opathy (OMIM 310400) [32]. However, enzyme staining
showed reduced central staining in some myofibres,
while electron microscopy showed foci of sarcomeric
dissolution, suggestive of cores. IHC for myosin con-
firmed the preservation of type II/fast myofibres and nu-
merous small type I myofibres. Thus a diagnosis of
congenital myopathy with fibre-type disproportion and
occasional minicores had been suggested (Fig. 2d-e).
This highlights that MTM1 cases can present with con-
genital weakness and muscle biopsies displaying features
of fibre type disproportion and minicores.
RYR1
The proband and affected sibling of Family 6 (Fig. 1d),
were born to consanguineous parents. The proband was
born at 30 weeks gestation with profound hypotonia, fa-
cial weakness, dysmorphic features and ambiguous geni-
talia, after a pregnancy complicated by fetal hypokinesia.
He died at 3 weeks of age. A subsequent pregnancy with
a female sibling was complicated by polyhydramnios. At
birth there was minimal limb movement, respiratory
distress necessitating mechanical ventilation, subcutane-
ous oedema, contractures of the hips and knees and
camptodactyly of the fingers. She died at 4 weeks of age.
Maternal testing for myotonic dystrophy (DM1) was
negative. Vastus lateralis biopsies from both babies
showed non-specific abnormalities of myofibre typing,
with type II myofibre predominance and numerous
small myofibres. Occasional minicores and cores were
seen in the proband but not his sibling. Neither had
nemaline bodies or histologic features of myotubular
myopathy. Exome sequencing performed on the proband
revealed two mutations in the ryanodine receptor gene
(RYR1, OMIM 180901): a novel heterozygous missense
mutation affecting a highly conserved amino acid
(Fig. 3b) (exon 36, c.5989G>A, p.Glu1997Lys) and a het-
erozygous previously-reported nonsense mutation (exon
20, c.2455C>T, p.Arg819* [33]). Sanger sequencing con-
firmed these mutations and showed co-segregation with
disease. Thus in this instance, the consanguinity does
not appear to be a contributing factor in the siblings’
disease. The nonsense mutation was previously identi-
fied in a 49-year old ambulant patient with a moderate
form of slowly-progressive myopathy with cores [33].
That patient also harboured a previously identified het-
erozygous missense mutation (p.Arg4558Gln) [33, 34].
Thus the same nonsense mutation, in combination with
different missense mutations, can result in variable phe-
notypes, from fetal hypokinesia and death in the peri-
natal period, to a mild delay in motor milestones and
normal life expectancy.
The proband in non-consanguineous Family 8 (Fig. 1e)
presented with non-immune hydrops fetalis and arthro-
gryposis, and was stillborn at 26 weeks gestation.
Autopsy showed multiple contractures and reduced
muscle bulk. Microscopically, there were marked dys-
trophic changes in all muscles examined (Fig. 2g). The
contactin-1 gene (CNTN1, OMIM 600016) was Sanger
sequenced but no mutations were identified. A subse-
quent pregnancy with a male fetus was complicated by
polyhyhydramnios, contractures, and in utero fetal de-
mise at 29 weeks gestation. Both affected individuals
were diagnosed with FADS and congenital muscular dys-
trophy. Exome sequencing of the proband identified two
previously reported heterozygous mutations in the RYR1
gene; a nonsense mutation (exon 41, c.6721C>T,
p.Arg2241* [35]) and a missense mutation (exon 101,
c.14645C>T, p.Thr4882Met [36]) associated with multi-
minicore disease and core rod disease, respectively.
Sanger sequencing confirmed compound heterozygosity
in both affected individuals, and showed that both par-
ents were carriers and that the unaffected sibling did not
harbour either mutation.
The affected individual in Family 13 was born to non-
consanguineous Turkish parents (Fig. 1f ) after reports of
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reduced intrauterine movement. He was delivered at
term by Caesarean section, due to poor positioning. At
birth bilateral humeral fractures were noted. He had a
diagnosis of osteogenesis imperfecta, and followed up
with alendronate treatment. He was referred to pediatric
neurology outpatient clinic at the age of 19 months
when the parents had concerns in terms of hypotonia
and delay in motor developmental milestones. At the
time, he remained hypotonic with a myopathic face and
high-arched palate. He had axial and vertical hypotonia,
head lag, facial weakness, and absence of deep tendon
reflexes. He could sit but not stand. The muscle biopsy
showed muscle tissue embedded in fibro-adipose tissue
with severe non-specific myopathic changes (Fig. 2f ).
There were hypertrophic and atrophic myofibres, central
nuclei, type II myofibre predominance and some core-like
regions on oxidative enzyme stains. Exome sequencing of
the proband revealed two pathogenic missense mutations
in the RYR1 gene, (exon 15, c.1589G>A, p.Arg530His [37],
exon 101, c.14645C>T, p.Thr4882Met [36]) which had
previously been associated with central core disease/ma-
lignant hyperthermia (MH) and core rod myopathy, re-
spectively. The p.Arg530His substitution was inherited
paternally, thus the presence of this MH (OMIM 145600)
susceptibility mutation in both the proband and asymp-
tomatic father changes their clinical management.
Thus, affected individuals in three families (Family 6,
8, and 13), harbored compound heterozygous mutations
in RYR1. Disease severity was much greater in the two
families possessing a nonsense (null) mutation as well as
a missense mutation (Family 6 and 8), resulting in death
at or soon after birth. The affected individual in the third
RYR1 family, (Family 13), possessed two missense muta-
tions, and survived infancy, albeit with severe muscle
Fig. 3 Histology of muscle biopsies from four families with mutations identified in the proband. Family 16 (a-c): h&e indicating variation in
myofibre diameter (a) and Gomori trichrome staining showing dark purple regions suggesting nemaline bodies (arrows) (b). Electron micrograph,
arrows indicate miliary nemaline bodies (c). (d) H&E stain of muscle from the proband in Family 14, indicating variation in myofibre size, central
and internal nuclei. (e) Staining for NADH-TR in muscle from the proband in Family 14 with arrows indicating reduced central staining indicative
of minicores. (f) H&E staining of muscle from the proband in Family 13 showing muscle tissue embedded in fibro-adipose tissue, with severe
myopathic, non-specific changes. (g) H&E staining of muscle from the proband in Family 8, demonstrating a severe non-specific picture
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weakness and motor delay. He had a rather static improv-
ing course with physiotherapy. These findings mirror
those of recent publications expanding the phenotypes as-
sociated with recessive RYR1 disease to include arthrogry-
posis multiplex congenita and fetal akinesia [9, 38, 39].
Despite RYR1 originally being described as a disease gene
for central core disease and minicore disease, cores are
seen in only a minority of recessive RYR1 cases, and are
less likely to be seen in cases with hypomorphic (null)
muations [38, 39]. In this study, cores were not a promin-
ent feature in two of the recessive RYR1 families, both of
which harboured a hypomorphic mutation.
NEB
A consanguineous family (Family 9) presented early in
pregnancy with monoamniotic male twins (Fig. 1g) and
a history of a previous fetus therapeutically aborted due
to hydrops fetalis at 19 weeks gestation. Ultrasound
scanning revealed severe hydrops in both fetuses, and
the pregnancy was terminated at 16 weeks gestation.
Post-mortem analysis of both twins showed bilateral
joint contractures, bilateral talipes, multiple pterygia,
hypertelorism and cystic hygromas. Muscle biopsies
were not taken. A diagnosis of fetal akinesia with lethal
multiple pterygia syndrome was made. Karyotyping
showed a normal 46XY karyotype, with no apparent
genomic imbalance. Exome sequencing was performed
on one twin, and a novel homozygous nonsense muta-
tion (exon 29, c.2920C>T, p.Arg974*) in the nebulin
gene (NEB; OMIM 161650) was identified. Sanger se-
quencing confirmed that both twins were homozygous
for this mutation and that each parent was a carrier
(Fig. 1). This mutation was included in the recent NEB
mutation update [40]. Although this case was diagnosed
as FADS/lethal multiple pterygia syndrome, recessive
mutations in the NEB gene are a known cause of NEM,
which in severe cases can have a FADS phenotype [41].
Without a muscle biopsy however, it cannot be deter-
mined whether these cases had nemaline myopathy.
In three additional families, diagnosed with NEM pre-
senting with fetal akinesia, single heterozygous patho-
genic mutations were identified in NEB by either exome
sequencing or NSES (Table 3). In Family 17 a known
splice-site mutation (intron 5, c.78+1G > A, [42]) was
identified, and in Family 19 a known frameshift mutation
(exon 55, c.7523_7526del4, p.Ile2508Thrfs*14, [43]), was
identified, both of which are associated with NEM. In
Family 18, a previously unpublished nonsense mutation
(exon 29, c.2864G>A, p.Trp955*) was identified. A com-
mon deletion of exon 55 of NEB, originating within the
Ashkenazi Jewish population, is known to cause a severe
NEM phenotype [44]. A heterozygous deletion of this
exon would not be identifiable through next generation
sequencing techniques. Deletion analysis was performed
on the affected individuals of Family 17 and Family 18,
which confirmed they did not have a deletion of this exon.
The proband in Family 19 could not have harboured a de-
letion of exon 55, since the exon 55 variant identified in
this proband was heterozygous. Although only single het-
erozygous mutations were identified in these three severe
NEM cases, given their severity and the absence of likely
pathogenic variants in the other known NEM genes, it is
likely that they are harbouring a second pathogenic NEB
variant that was not identified by next generation sequen-
cing. In support of AR NEM, Family 18 and 19 both had a
previously affected fetus. In further support that these
cases (three of nine NEM families, 33 %) are harbouring
an additional pathogenic NEB variant, only one truncating
NEB variant was identified by next generation sequencing
in non-NEM cases, of which we have sequenced and ana-
lysed in excess of >500 probands (~0.2 %). Due to the
highly repetitive nature of exons 83–105 of NEB, next
generation sequencing is unable to accurately sequence
and map this region; in addition, next generation sequen-
cing data is not reliable for the detection of small CNVs.
However a targeted NEB array CGH has been developed
as an adjunct to overcome these limitations [45] and has
recently identified a recurrent CNV within this triplicated
repeat [46].
Therefore, of the nine NEM cases in our cohort, five
cases had mutations in the newly described genes
KLHL40 and KLHL41, and an additional three cases are
thought likely to harbour a second pathogenic mutation
in NEB. It is likely that many undiagnosed NEM cases
are due to mutations in NEB, however due to its size it
has not been routinely screened. With the introduction
of next generation sequencing techniques, more NEB-re-
lated NEM cases are beginning to be identified. This
may mean that there are not as many new NEM genes
to find as might have been thought.
GBE1
A non-consanguineous family (Family 2) presented with
recurrent fetal akinesia and multiple pterygium syndrome
Table 3 Single heterozygous mutations identified in NEB in three families presenting with fetal hypokinesia-NEM
Family Exon/(Intron) c. DNA change NM_001164507.1 Amino acid change Comments
17 (5) c.78+1G>A
18 29 c.2864G>A p.Trp955* Also present in affected sib
19 55 c.7523_7526del4 p.Ile2508Thrfs* Affected sib (no DNA available)
Todd et al. Orphanet Journal of Rare Diseases  (2015) 10:148 Page 9 of 14
[23]. We identified compound heterozygous mutations in
the gene GBE1, a known splice site mutation (intron 5,
c.691+2T>C) associated with a non-lethal neonatal glyco-
genosis type IV, and a missense mutation (exon 7,
c.956A>G, p.His319Arg). This report extended the pheno-
typic spectrum of GBE1 disease to include lethal multiple
pterygium syndrome [23].
Mutations in known disease genes for arthrogryposes
CHRND
The proband in Family 10 was the first child to non-
consanguineous parents, born following an IVF preg-
nancy, (Fig. 1h). A routine 20-week ultrasound identi-
fied bilateral fetal talipes. Chromosome microarray
was normal. The fetal phenotype evolved with polyhy-
dramnios, fetal micrognathia and an absence of hand
movements noted at 32 weeks. The polyhydramnios
required three amnioreduction procedures. The male
infant was delivered by elective Caesarian section for
placenta praevia at 37 weeks gestation and weighed
2.82 kg. He was intubated and ventilated at 10 mi-
nutes for apnoea and poor respiratory effort after
APGARS of 51, 65 and 710. He had micrognathia,
cryptorchidism, a left single palmar crease, bilateral
talipes, moderate large joint contractions, hypotonia,
an absent gag/suck, and paucity of movement. He de-
veloped a weak suck and infrequent antigravity move-
ment of the fingers after a week. Prader-Willi
syndrome, SMA and myotonic dystrophy were ex-
cluded. Endocrine and metabolic investigations were
normal as was the ophthalmologic examination. Brain
MRI showed a right MCA infarct in the context of
positive maternal serology for SLE. Multiple attempts
to extubate the patient to CPAP failed. Ongoing ven-
tilatory support was considered futile and was with-
drawn at 4 weeks of age. Exome sequencing was
performed and two novel heterozygous mutations
were identified in CHRND (OMIM 100720) that en-
codes the delta-subunit of the acetylcholine receptor
(AChR) [47]. A missense mutation (c.769T>C) in
exon 7 that resulted in substitution of a highly con-
served amino acid (p.Cys257Arg, Fig. 3c) and a
frameshift mutation in exon 11 (c.1315delG,
p.Val439Trpfs*11). To our knowledge neither of these
mutations have been previously reported and are not
listed in the CHRND locus-specific database (http://
www.dmd.nl/nmdb/home.php?select_db=CHRND).
Sanger sequencing confirmed the presence of the mu-
tations in the affected individual and showed each
parent was a carrier of one of the variants. The
mother conceived a second time, naturally. Prenatal
diagnosis was performed and the fetus had both vari-
ants. The pregnancy was terminated.
Studies in HEK cells, found that cell surface expression
levels of AChRs harbouring the δC257R subunit to be
approximately 20 % of wild-type (Fig. 4). This result is
consistent with the c.769T>C mutation (in combination
with c.1315delG, p.Val439Trpfs*11 on the second allele)
underlying a congenital myasthenic syndrome due to
AChR deficiency. The mother is currently pregnant and
is approaching term with a healthy fetus following PGD.
Mutations of CHNRD typically result in congenital my-
asthenic syndromes (OMIM 608930 (fast-channel) and
601462 (slow-channel) [48, 49]). but have also more re-
cently been associated with lethal multiple pterygium
syndrome [50]. In two families presenting with recurrent
lethal multiple pterygium syndrome, resulting in termi-
nations during the second trimester of pregnancy, null
mutations of CHRND were identified (one consanguin-
eous family with a homozygous p.Trp57* mutation and
one with compound heterozygous p. Phe74Leu and
p.Arg464* mutations). Substitutions of amino acids in
close proximity to Cys257 have been shown to cause
congenital myasthenia and impaired channel function
(p.Pro250Gln [51] and p.Ser268Phe [48]).
CHRNG
The affected female individual in Family 15 was born to
unrelated parents (Fig. 1i). At birth there was arthrogry-
posis with distinctive shin dimples. The clinical picture
of this patient is presented in Hall et al., (Patient 10)
[52]. NSES was performed on the proband and revealed
a known frequent homozygous frameshift mutation
(exon 5, c.459dupA, p. Val154Serfs*24) in the gene en-
coding the gamma-subunit of the AChR (CHRNG;
Fig. 4 Expression of wild-type (αβδε) and mutant (αβδC257Rε)
acetylcholine receptors (AChR) in HEK 293 cells. AChR expression
was determined through the binding of 125I α-Bungarotoxin (125I α-
BuTx) to AChR on the cell surface (n = 6). Note: numbering of the
mutation includes the pre-peptide sequence
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OMIM 100730) [53, 54]. Sanger sequencing confirmed
the presence of the mutation in the affected individual,
as well as showing each parent had the mutation in the
heterozygous state. Given the unique presentation of
arthrogryposis with shin dimples in this case and others
harbouring CHRNG mutations [54], CHRNG should be
considered in individuals presenting with this particular
phenotype.
MYH3
The proband in Family 1 was born from unaffected
parents and has an unaffected sibling (Fig. 1j). He
presented with Freeman-Sheldon Syndrome (DA2A,
OMIM 193700) [55] and on examination at 2 years
of age he showed some facial features and proximal
weakness. Exome sequencing of the proband demon-
strated heterozygosity for a mutation in MYH3 (exon
18, c.2015G>A, p.Arg672His; OMIM 160720 [55];)
previously associated with Freeman-Sheldon syn-
drome. Sanger sequencing confirmed the presence of
this mutation in the proband as well as its absence in
the unaffected sibling and both unaffected parents,
confirming the mutation was de novo.
The male proband from Family 11, was born from an
unaffected mother, but affected father (Fig. 1k). Both
proband and the father were born with a very typical
Sheldon-Hall distal arthrogryposis (DA2B) phenotype.
Sheldon-Hall syndrome can be caused by autosomal
dominant or de novo mutations in a number of genes. In
this kindred, screening of TPM2 and TNNI2 identified
no mutations. On NSES, however, a known heterozygous
MYH3 mutation (exon 12, c.1123G>A, p.Glu375Lys
[55]) previously associated with Freeman-Sheldon syn-
drome, was identified. Sanger sequencing confirmed the
mutation in both the proband and his affected father,
confirming autosomal dominant inheritance.
ECEL1
Non-consanguineous Family 7, previously described in
[56], was also part of this cohort study. The proband
was born from an uncomplicated pregnancy with ex-
tended hips, multiple arthrogrypotic features, multiple
pterygium, adducted thumbs and bilateral ptosis. The
couple presented when pregnant again, and on ultra-
sound at 20 weeks the fetus appeared to have similar
features to those of the proband. The pterygia and ptosis
led to consideration of multiple pterygium syndrome
(Table 1). Exome sequencing revealed compound hetero-
zygous mutations in ECEL1 (OMIM 605896), a missense
substitution (c.1531G>A, p.Gly511Ser) and a essential
splice-site mutation (c.1797-1G>A). Mutations in ECEL1
are associated with distal arthrogryposis type 5D (OMIM
615065), and the clinical presentation was in keeping with
those recently described for DA5D [13, 57], although pte-
rygia was a more prominent feature in this family.
In another cohort study, Laquerriere et al. identified
two novel genes (CNTNAP1 and ADCY6) for severe
arthrogryposis multiplex congenita (AMC) by exome se-
quencing, and achieved a genetic diagnosis for 24 of 31
multiplex and/or consanguineous AMC families studied
(>75 %). This highlights the importance of working with
well-phenotyped cohorts [9]. Mutations in CNTNAP1
were identified in four of their 31 families, suggesting
that mutations in this gene underlie a significant propor-
tion of recessive AMC cases.
Results from our study, and that of Laquerriere et al.,
suggest that there are further arthrogryposis disease
genes to be identified [9]. ADCY6 and CNTNAP1 are
both involved in axonal function [9], as is ECEL1 [57].
GPR126 is critical for myelination of peripheral nerves
[58] and we identified AMC patients with loss-of-
function mutations in GPR126 [30]. Genes involved in
axonal function should therefore be considered as candi-
dates for arthrogryposis, in addition to skeletal muscle
contractile proteins.
Our study highlights the widening spectrum of phe-
notypes associated with mutations in known fetal
akinesia, arthrogryposis and myopathy genes, as is in-
creasingly demonstrated for other neuromuscular dis-
orders [26, 59, 60]. As sequencing of targeted gene
panels or exome sequencing becomes the mainstay of
genetic diagnostics [61, 62], it is likely that there will
be greater broadening of genotype-phenotype correla-
tions for neuromuscular diseases. With the over-
whelming amount of genetic information obtained via
next generation sequencing, the reliability of meticu-
lously curated locus-specific databases, the availability
of large exome datasets from ethnically matched ref-
erence populations and appropriate functional and/or
protein studies will be critical to obtaining accurate
genetic diagnosis. Given that numerous novel disease
genes and mutations are being described in non-
Caucasian inbred populations [63] and genetic isolates
[64], there is a real need for exome sequencing of
healthy individuals within these populations.
Within our cohort, three novel disease genes were ini-
tially identified by exome sequencing of single probands
(GPR126, KLHL41 and SPEG). The success of disease gene
discovery in NEM (KLHL40, KLHL41, LMOD3, MYO18B)
and centronuclear myopathies (SPEG) is likely due to the
ability to identify patients with a very similar presentation
(clinically and based upon very specific muscle biopsy
findings) such as to enable screening of candidate genes in
patients with the same disease [21, 65].
For fetal hypokinesia and arthrogryposis cases, it is
more difficult to deeply phenotype the patients, due in
many cases to the poor preservation of fetal tissue and the
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lack of specific pathological hallmarks from biopsy or aut-
opsy material. A recent study describes exome sequencing
of 143 multiplex consanguineous families, in which 33
novel candidate neurogenic disease genes were identified
[63], highlighting the value of studying consanguineous
families. As a comparison, only three of the 20 (15 %)
genetically-unresolved cases were consanguineous whereas
seven of 18 of the genetically-diagnosed cases were consan-
guineous (39 %, Additional file 1: Table S1), thus one is 2.5-
times more likely to identify the causative disease gene in
consanguineous families. A genetic diagnosis was achieved
in ten of 16 congenital myopathy cases (63 %) and six of 13
arthrogryposis cases (46 %) but only 22 % of fetal akinesia
cases (two of nine). It is also possible that the cause of dis-
ease, in some of the isolated cases (particularly those diag-
nosed with fetal akinesia), is not due to a monogenic
disorder but may be environmental and/or polygenic. In
families with multiple affected siblings and normal CGH ar-
rays, we will pursue whole genome sequencing and/or
RNA-seq of target tissue cDNA to try to identify novel dis-
ease genes and/or mechanisms.
Conclusions
In summary, this study highlights the use of next generation
sequencing to genetically diagnose 47 % of cases within a
heterogeneous severe neuromuscular disease cohort. The
study has also resulted in the identification of four novel
neuromuscular disease genes, and has led to the identifica-
tion of a novel mechanism of sarcomere assembly and
muscle dysfunction involving KLHL40, KLHL41 and
LMOD3 [21, 66, 67]. Finally, this study has contributed to
extending the phenotypic spectrum of CHRNG, ECEL1,
GBE1 and RYR1.
Additional file
Additional file 1: Table S1. For each family the affected individuals
sequenced are shown as well as the type of NGS that was performed for
each patient. The disease group and consanguinity for each family is also
indicated as are the coverage statistics for each sample and NGS.
(DOCX 21 kb)
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